Weight gain is not an officially recognized side effect of Emgality (galcanezumab), and it does not appear anywhere on the drug’s FDA-approved label. Yet many people taking this migraine prevention medication report gaining weight, and there are biologically plausible reasons why blocking the molecule Emgality targets could shift your body’s energy balance. The short answer: the science is complicated, the clinical trials didn’t flag it, but the underlying biology suggests it’s not all in your head.
What Emgality Does in Your Body
Emgality works by neutralizing a signaling molecule called CGRP (calcitonin gene-related peptide). CGRP plays a central role in migraine attacks, which is why blocking it helps prevent them. But CGRP isn’t a one-trick molecule. It’s active throughout your nervous system, your gut, and your metabolic pathways, and shutting it down has ripple effects beyond headache prevention.
CGRP’s Role in Appetite and Satiety
One of the most relevant functions of CGRP for weight is its role in telling your brain when to stop eating. Neurons that produce CGRP in a brain region called the parabrachial nucleus act as a brake on meal size. When researchers inactivated these CGRP neurons in mice, the animals ate significantly larger meals and became insensitive to the normal hormonal signals that create the feeling of fullness after eating. Meal frequency dropped slightly to compensate, but overall food intake still increased.
These same CGRP neurons are directly connected to hunger-promoting neurons in the hypothalamus. When the hunger circuit fires, it suppresses the CGRP satiety neurons, which is part of how your brain drives you to keep eating when you’re genuinely hungry. This means CGRP sits at a critical intersection where hunger and fullness signals meet to regulate how much you eat at any given meal. Blocking CGRP systemically with a drug like Emgality could, in theory, weaken those “I’m full” signals.
Animal research supports this idea from another angle. When CGRP is administered directly into the brain, it reduces food intake and body weight. Conversely, when researchers give animals drugs that block the CGRP receptor, food intake, body weight, and body fat all increase. The effects are potent enough that researchers believe CGRP normally functions as a signal that informs the central nervous system about nutrient availability after meals.
Effects on Metabolism and GLP-1
Beyond appetite, CGRP appears to influence metabolism in ways that could affect weight. CGRP interacts with GLP-1, the same gut hormone targeted by popular weight loss medications like semaglutide. The two molecules have a bidirectional relationship: CGRP boosts GLP-1 levels by more than 60%, and GLP-1 in turn stimulates CGRP release. Anti-CGRP drugs appear to reduce GLP-1 secretion, which could blunt one of the body’s natural mechanisms for controlling blood sugar and promoting satiety after meals.
CGRP also influences insulin release, reducing it after meals. And research in mice genetically engineered to lack CGRP showed a reduction in diet-induced obesity, suggesting the molecule plays some role in how the body handles excess calories. Paradoxically, this might seem to suggest blocking CGRP would help with weight, but the full picture is more nuanced. CGRP both contributes to certain metabolic processes that promote fat storage and simultaneously reduces appetite through brain circuits. Blocking it removes both effects, and the net result likely varies from person to person.
Changes in Gut Function
CGRP normally slows gastrointestinal transit and gastric emptying, meaning it keeps food moving through your digestive system at a measured pace. When you block CGRP, the resulting changes in gut motility may contribute to digestive symptoms. People on CGRP-blocking medications commonly report stomach pain, nausea, and other gastrointestinal issues. These gut changes could indirectly influence how your body absorbs nutrients and how hungry or full you feel between meals, though the direct link to weight gain through this pathway is less clear than the appetite signaling mechanism.
Why Clinical Trials Didn’t Catch It
The clinical trials that led to Emgality’s approval tracked side effects for up to six months. The only adverse reaction that showed up at meaningful rates was injection site reactions, occurring in about 18% of patients on Emgality compared to 13% on placebo. Only 1.8% of patients dropped out due to side effects. Weight gain was not reported at rates that distinguished it from placebo.
There are a few reasons clinical trials can miss a side effect like this. Six months is a relatively short window for detecting gradual weight changes, especially when the effect might be modest, perhaps a few pounds that accumulate over a year or more. Trials also typically enroll carefully selected populations and may not capture the full range of metabolic responses seen in the real world. The FDA’s postmarketing surveillance for Emgality has identified a handful of additional side effects since approval (including high blood pressure and a circulation condition called Raynaud’s phenomenon), but weight gain has not been formally added to the label.
What Might Actually Be Happening
If you’re gaining weight on Emgality, several factors could be working together. The most scientifically supported explanation involves weakened satiety signaling. With less CGRP activity in your brain, you may not feel as full after eating the same amount of food, leading to slightly larger meals or more frequent snacking without being consciously aware of it. Reduced GLP-1 levels could compound this effect.
There’s also a lifestyle factor worth considering. Chronic migraine is debilitating, and people who find effective prevention often become more active, change their eating patterns, or simply feel well enough to eat more regularly. Some older migraine preventives, like certain antidepressants and anti-seizure medications, suppress appetite or cause nausea as side effects. Switching to Emgality removes those appetite-suppressing effects, which can feel like weight gain caused by the new drug when it’s really the absence of the old one.
Individual variation matters enormously here. The competing roles CGRP plays in metabolism (promoting fat storage in some pathways, suppressing appetite in others) mean that blocking it could tip the scales differently depending on your genetics, baseline metabolism, diet, and activity level. Some people on Emgality report no weight change at all, while others notice a steady climb of 5 to 15 pounds over the first year.
What You Can Do About It
Tracking your food intake for a few weeks after starting Emgality can help you spot whether your portion sizes or snacking patterns have shifted. Because the most likely mechanism involves reduced fullness signals, paying attention to hunger cues and eating more slowly may help compensate. Protein and fiber at meals tend to activate fullness pathways that don’t rely solely on CGRP, so adjusting the composition of your meals could make a difference.
If you’re experiencing significant weight gain and it’s affecting your quality of life, it’s worth weighing (no pun intended) against the benefit you’re getting from migraine prevention. For many people, fewer migraines is worth a few extra pounds. For others, especially those with metabolic conditions, the tradeoff may not be as clear-cut, and other CGRP-blocking medications or different classes of preventives might be worth exploring.